Regulation of nitric oxide consumption by hypoxic red blood cells by Tae H. Han et al.
Regulation of nitric oxide consumption by hypoxic
red blood cells
Tae H. Han*, Erion Qamirani†, Allyson G. Nelson‡, Daniel R. Hyduke*, Gautam Chaudhuri‡§, Lih Kuo†,
and James C. Liao*¶
Departments of *Chemical Engineering, ‡Medical and Molecular Pharmacology, and §Obstetrics and Gynecology, University of California, Los Angeles,
CA 90095; and †Department of Medical Physiology, Texas A&M University System Health Science Center, College Station, TX 77843
Edited by Louis J. Ignarro, University of California School of Medicine, Los Angeles, CA, and approved August 15, 2003 (received for review June 4, 2003)
The homeostasis of nitric oxide (NO) is attained through a balance
between its production and consumption. Shifts in NO bioavail-
ability have been linked to a variety of diseases. Although the
regulation of NO production has been well documented, its con-
sumption is largely thought to be unregulated. Here, we have
demonstrated that under hypoxic conditions, NO accelerates its
own consumption by increasing its entry into RBCs. When RBCs
were exposed to NO (1:400 NOheme ratio) under hypoxic condi-
tions to form HbFe(II)NO, the consumption rate of NO increased
significantly. This increase in NO consumption converted the bio-
activity of serotonin from a vasodilator to a vasoconstrictor in
isolated coronary arterioles. We identified HbFe(II)NO as a poten-
tial mediator of accelerated NO consumption. Accelerated NO
consumption by HbFe(II)NO-bearing RBCs may contribute to hy-
poxic pulmonary vasoconstriction and the rebound effect seen on
termination of NO inhalation therapy. Furthermore, accelerated
NO consumption may exacerbate ischemia-mediated vasospasm
and nitrate tolerance. Finally, this phenomenon may be an evolved
mechanism to stabilize the vasculature in sepsis.
N itric oxide (NO) is a signaling molecule produced by threeisoforms of NO synthases for a variety of functions, includ-
ing regulation of vasculature, participation in immune responses,
and neuronal signalingregulation. Regulation of NO concen-
tration has generated considerable interest, because changes in
NO bioavailability have been linked to a variety of disease states
(1). The homeostasis of NO is attained through a balance
between its production and consumption. In the vasculature,
RBCs are the major scavenger of NO, because RBCs contain
high concentrations of Hb, an effective NO scavenger.
HbFe(II)O2 converts NO to nitrate, whereas HbFe(II) binds to
NO to form HbFe(II)NO. Because Hb efficiently consumes NO
at extremely high rates, the consumption of NO has generally
been considered to be unregulated.
However, when Hb is enclosed within RBCs, its consumption
of NO decreases significantly (2–5). This reduction in NO
consumption has been attributed to (i) the RBC-free zone near
the vessel wall (2), (ii) extracellular diffusion resistance from the
bulk solution to the RBC surface (3), and (iii) the intracellular
barrier associated with the RBC membrane and membrane
skeleton (4). In support of the last mechanism, Huang et al. (4)
have demonstrated that chemical modifications to the RBC
result in the modulation of NO bioavailability by altering the rate
RBCs consume NO. This result suggested that changes to the
consumption of NO can potentially be an effective means to
regulate NO bioavailability.
To investigate the physiological relevance of this potential
regulatory mechanism, we tested various molecules that can
serve as a physiological modulator of NO consumption. Surpris-
ingly, we found that NO consumption by RBCs can bemodulated
by NO itself at concentrations found in vivo, but only under
hypoxic conditions that allow for the formation of HbFe(II)NO.
This modulation was reversible, because HbFe(II)NO was un-
stable under aerobic conditions. These results demonstrated that
regulation of NO consumption can occur under physiological
conditions and may indeed explain, in part, many unsolved
puzzles, such as hypoxic pulmonary vasoconstriction (HPV), the
rebound effect on termination of NO inhalation therapy, and
ischemic vasospasm. In addition, increased uptake of NO may
stabilize the vasculature during sepsis.
Materials and Methods
Materials. All NO donors were purchased from Cayman Chem-
ical (Ann Arbor, MI). Glucose, potassium cyanide, and sodium
hydroxide were purchased from Fisher Scientific. All other
chemicals were purchased from Sigma.
Treatment of RBCs. Isolated and washed human or bovine RBCs
(4) were held under hypoxic conditions with ultrahigh-purity
argon (1% PO2) until the desired intracellular HbFe(II)O2
fraction was reached. Hypoxic RBCs were washed by centrifu-
gation at 800  g and by aspirating the supernatant. A subset of
these RBCs was treated with NO generated from proline
2,2-(hydroxynitrosohydrazino) (NONOate) or diethylamine–
NONOate at NOHb ratios of 1:2,000 to 1:200, on a heme basis.
The suspension of RBCs and NO donor was incubated for at
least two half-lives of the respective NO donor. Both NO-treated
and untreated RBCs were then washed three times in 50:1 ratios
with isotonic 40 mMHepes buffer containing 5 mM glucose (pH
7.4) under hypoxic (1% PO2) or normoxic conditions (21%
PO2). The hematocrit (Hct) was adjusted to 15% for the
competition assay.
Competition Assay. This procedure has been described (6, 7), and
a detailed description of the procedure along with the computer
program for calculating the kinetic constant is available online
(www.seas.ucla.eduliaoj). Briefly, each test consisted of at
least three solutions run simultaneously: cell-free HbFe(II)O2
with spermineNONOate (SpNO) donor in buffer, cell-free
HbFe(II)O2 in a suspension of untreated bovine RBCs with
SpNO, and cell-free HbFe(II)O2 in a suspension of treated
bovine RBCs with SpNO. Each solution (15 ml) was loaded
into a 20-ml syringe. The syringes were placed in a rotator to
keep the cells uniformly dispersed. Samples were taken every 20
min and centrifuged (20 s at 16,000 g) to pellet the RBCs, and
the supernatant was assayed for HbFe(II)O2 and methemoglo-
bin [HbFe(III)] on a Beckman DU 640 spectrophotometer. For
competition assays performed under anaerobic conditions,
HbFe(III) and HbFe(II)NO were measured by electron para-
magnetic resonance (EPR, described later).
Microvessel Assay. The methodologies for isolation of porcine
coronary arterioles have been described (8). Briefly, pigs were
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anesthetized with pentobarbital sodium (20 mgkg, i.v.) and
ventilated. The heart was removed and immediately placed in
iced saline. Subepicardial arterioles (1.5-mm length, 50- to
100-m i.d., in situ) were carefully dissected and cannulated with
glass micropipettes. The vessels were then pressurized to 60 cm
of H2O intraluminal pressure without flow and incubated at 37°C
throughout the duration of the experiment. After developing a
stable basal tone, vessel i.d. changes, in response to an accumu-
lating increase in 5-hydroxytryptamine (5-HT, serotonin) con-
centration, were recorded by using videomicroscopic techniques.
After establishing the control 5-HT response, the vessel bath was
washed with physiological salt solution, and untreated or NO-
pretreated hypoxic RBCs (40% Hct) were introduced into the
lumen. The diameter changes in response to 5-HT stimulation
were reassessed.
Aortic Ring Assay. The preparation of rat aortic rings was similar
to that described previously (9). Briefly, the thoracic aortas of six
female Sprague–Dawley (Harlan–Sprague–Dawley) rats were
carefully removed and cut into 5-mm transverse rings, four to five
per animal). The rings were mounted in tissue baths and
incubated in Krebs solution (10 ml) gassed with 95% oxygen and
5% carbon dioxide and maintained at 37°C. The rings were
stretched to a resting tension of 1 g. The amount of resting
tension was determined in previous experiments performed in
our laboratory. After determining maximal constriction to high-
potassium Krebs and confirming the presence of a functional
endothelium by relaxation to acetylcholine, the vessels were
preconstricted with phenylephrine to elicit 50–60% of maximal
constrictions. In each experiment, two to three vessels were
incubated with either untreated or NO-pretreated hypoxic RBCs
(1% Hct). The aortic ring constriction was measured and
reported as a percentage increase over baseline.
Measurement of HbFe(II)NO. The allosteric state of HbFe(II)NO in
whole RBCs was probed with EPR, as described (10). Briefly,
200 l of each sample was introduced into 3-mm-i.d. clear
fused-quartz tubes and plunged into liquid nitrogen. The EPR
spectrum of each sample was measured on a Bruker (Billerica,
MA) EMX spectrometer in the X band at 77 K by using a suprasil
liquid-nitrogen finger Dewar (Wilmad, Buena, NY) in a Bruker
4119HS-W1 high-sensitivity cavity. Detailed spectra of
HbFe(II)NO were taken at a modulation amplitude of 4 G was
used with an 81.92-ms time constant and a sweep width of 400
G centered at 3,288 G. The spectrometer was operated at 9.35
GHz, 10.1-mW microwave power, 100-kHz modulation fre-
quency. Under these conditions, the power was not saturated.
Two scans were taken. Quantification of HbFe(II)NO was done
by double integration by using WINEPR SYSTEM 2.11 (Bruker) and
comparison with a calibration curve generated by measuring
UV-visible spectroscopy standardized HbFe(II)NO samples in
the EPR instrument.
Tomeasure HbFe(II)NO in crude preparations of membranes
and cytoplasmic fractions of NO pretreated hypoxic RBCs, a
method based on chemiluminescence was used (11). Because of
HbFe(II)NO dilution from the preparation of the membrane
fraction, EPR could not be used. Treated RBCs were lysed 1:40
with 10 mM phosphate buffer (pH 7.4, 4°C) and washed twice
at the same ratio with centrifugation at 18,000  g (4°C). All
solutions were maintained at 4°C to minimize HbFe(II)NO
degradation. Cytoplasmic and membrane-rich fractions were
treated with nonidet-P40 and mercuric chloride. Background
nitrite was removed by filtration through a Sephadex G-25
column and treatment with acidified sulfanilamide. Each frac-
tion was injected into a reaction chamber containing a solution
of 50 mg of potassium iodide and one iodine crystal in 9 ml of
80% acetic acid. The NO evolved from the reaction chamber was
carried in ultrahigh-purity helium (Airgas, Radnor, PA) to a gas
wash bottle containing a 1 M NaOH solution and then to a
Sievers NO Analyzer 280 (Ionics Instruments, Boulder, CO) to
measure NO quantities by the chemiluminescence reaction with
ozone. Data were recorded with NOANALYSIS 3.21 LIQUID soft-
ware provided by Sievers and analyzed with PEAKFIT 4.11 (Systat,
Richmond, CA). The concentration of NO was calculated from
a mass-calibrated nitrite calibration curve, as described in the
Sievers NO Analyzer 280 operation manual.
Results
NO Pretreatment of Hypoxic RBCs Increased NO Consumption. To
determine whether the rate of NO consumption by RBCs is
regulated by physiological variables such as NO and O2 concen-
trations, we tested the effect of NO pretreatment on RBCs at Hb
oxygen saturations ranging from 0% to 100%. In vivo, oxygen
saturation can be as low as 10% locally (12). Total NO generated
was in the low micromolar range from an NO donor (diethyl-
amine–NONOate or proline NONOate). After NO pretreat-
ment under various oxygen saturation conditions, the competi-
tion assay was conducted under aerobic conditions. In this assay,
RBCs compete with extracellular HbFe(II)O2 for NO generated
from SpNO, a slow-releasing NO donor. The production of
extracellular HbFe(III) from the reaction of NO was measured
to determine the rate of NO uptake by RBCs. The total amount
of NO released from the NO donor was measured by the
formation of HbFe(III) in a solution containing only the NO
donor and HbFe(II)O2. In the presence of NO-pretreated
hypoxic RBCs, less extracellular HbFe(III) formation was mea-
sured compared with the control sample, untreated hypoxic
RBCs (Fig. 1a), suggesting that NO-pretreated hypoxic RBCs
consume NO more rapidly than untreated hypoxic RBCs. Be-
cause the competition assay depends on the accurate measure-
ment of the NO reaction with HbFe(II)O2, whether NO-
pretreated RBCs released reducing or oxidizing species that may
skew these results was determined. Incubation of the NO-
pretreated or untreated RBCs in solutions of HbFe(II)O2 or
HbFe(III) (four separate samples, n  5) resulted in no change
in the extracellular species (data not shown). Hence, both
pretreated and untreated RBCs neither oxidize nor reduce
extracellular Hb under these conditions. In particular, NO was
not exported from NO-pretreated RBC under this condition.
Because less HbFe(III) is formed in the presence of hypoxic
RBCs pretreated with NO, these pretreated RBCs must con-
sume NO more rapidly than the untreated RBCs. This result
indicates that the entry of NO into the pretreated RBCs is
accelerated compared with the untreated RBCs.
Interestingly, the oxygen saturation of RBCs during NO
pretreatment was found to be inversely proportional to the
NO consumption rate. Because the potential product,
HbFe(II)NO, is unstable under aerobic conditions, we also
conducted the competition assay under anaerobic conditions. In
this case, the formation of extracellular HbFe(III) and
HbFe(II)NO was measured by EPR. Indeed, when both pre-
treatment and the competition assay were performed under
anaerobic conditions, the NO consumption rate increased by
69%, compared with untreated RBCs (Fig. 1b). This effect
diminished as the oxygen saturation of RBCs increased and was
not seen with pretreatment under normoxic conditions. The
difference in NO uptake may stem from the balance of
HbFe(III) andHbFe(II)NO formed under difference Hb oxygen
saturations. The formation of small quantities of HbFe(III), as
would form under these conditions, does not modify the NO
uptake rate (3, 7). On reoxygenation (21% PO2), the NO-
pretreated RBCs continued to consume NO faster (32  13%)
(Fig. 1c) compared with the sham controls. Thus, the increased
consumption of NO by these pretreated RBCs appears to be
directly related to the Hb status within RBC. Interestingly, after
incubating the NO-pretreated RBCs for 4 h under aerobic
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conditions (21%PO2), the NO uptake rate reverted to that of the
untreated RBC.
HbFe(II)NO Formed from NO Pretreatment of Hypoxic RBCs. Because
the effect of NO-pretreated RBCs was seen under hypoxic
conditions and was reversible on reoxygenation, HbFe(II)NO
was an attractive candidate responsible for accelerated NO
consumption. Indeed, the rate of NO uptake correlated with the
HbFe(II)NO content (Fig. 1d) in RBC, although this did not
imply a causative relationship. At HbFe(II)NO of 0.05% or
higher, the NO uptake rate of RBCs pretreated with NO under
hypoxic conditions was greater than untreated RBCs (Fig. 1d).
At ratios 0.03%, the NO uptake rate of RBCs pretreated with
NO under hypoxic conditions did not statistically differ from
untreated RBCs.
To further characterize the products of the NO reaction with
hypoxic RBC, we used EPR to determine the heme state of
HbFe(II)NO in RBC. The EPR spectrum (Fig. 2) showed that
the NO reaction with hypoxic RBC led to the formation of the
five-coordinate NO- heme adduct, as illustrated by the char-
acteristic hyperfine splitting. The NO- heme adduct under
hypoxic conditions has been shown to be the five-coordinated
‘‘super T’’ state (13). On reoxygenation, it becomes six-
coordinated, and the hyperfine structure disappears (Fig. 2).
This result demonstrated that NO was bound to the  hemes
after its entry into hypoxic RBCs. Measurement of RBCs
pretreated with NO under normoxic conditions did not yield a
HbFe(II)NO signal, similar to studies with cell-free Hb (10).
S-nitrosohemoglobin was not detected by using an I3
 ozone-
based chemiluminescence assay (11, 14) (data not shown).
Therefore, the formation of HbFe(II)NO in RBC is most likely
responsible for the accelerated NO uptake rate.
Because NO must enter the RBC through the cytoskeletal
barrier, it is expected that the ratio of HbFe(II)NO to total Hb
should be higher on the membrane than in the cytoplasm
fraction. In addition, evidence for the modulation of NO entry
proceeding through alterations of the membrane skeleton asso-
ciation to the membrane has been presented previously (4). To
test this hypothesis, the ratio of membrane-associated
HbFe(II)NO to total Hb was measured. The ratio was found to
be 	85% higher in the membrane fraction than in the cytoplas-
mic fraction (Table 1). Hence, the observed increase in NO entry
may stem from alterations due to the presence of HbFe(II)NO
in the membrane fraction of the RBC.
HbFe(II)NO-Containing RBCs Converted 5-HT from a Vasodilator to a
Vasoconstrictor. To explore the physiological relevance of this
regulation, we used isolated porcine coronary microvessels (100
m in diameter) as a bioassay. 5-HT was used to induce
NO-mediated dilation in the presence of NO-pretreated or
untreated RBCs. 5-HT is a vasoactive agent that produces two
opposing vasomotor responses in coronary vessels, i.e., dilation
via NO release from endothelium and constriction via direct
activation of 5-HT receptors on smooth muscle (15, 16). In intact
isolated porcine coronary arterioles, 5-HT induced vasodilation
(Fig. 3). Addition of 5-HT to arterioles containing intraluminal
RBCs (40% Hct) that received sham treatment resulted in
vasodilation, although attenuated compared with the buffer
Fig. 1. Pretreatment of hypoxic RBCs with NO increased the NO consumption
rate as measured by the competition assay. (a) The decreased production of
HbFe(III) in the extracellular space suggested that NO was consumed more
rapidly by hypoxic RBCs pretreated with NO (open squares) compared with
untreated RBCs (filled squares). The total amount of NO released by the NO
donor in the competition assay was measured by the formation of HbFe(III) in
a solution of NO donor and cell-free HbFe(II)O2 (filled circles). (b) Conversion
of HbFe(III) production to rates of NO uptake demonstrated hypoxic RBCs
pretreated with NO consume NO more rapidly. NO entry into hypoxic
RBCs pretreated with NO was more rapid than NO entry into untreated RBCs.
Pretreatment of RBCs with NO under normoxic conditions (21% PO2) results in
no change in the rate of NO uptake (P 0.05, n 4–8). (c) When tested under
anaerobic conditions (
NOO2), the consumption of NO by NO-pretreated
hypoxic RBCs increased 69  16% (P  0.01, n  8). Reoxygenating RBCs
pretreated with NO under hypoxic conditions by washing with oxygenated
buffer and performing the competition assay under normoxic conditions
(21% PO2) (
NO
O2), the rate of NO consumption remained greater than
that of untreated RBCs (31 13%) (P 0.01, n 8). Washing NO-pretreated
hypoxic RBCs with oxygenated buffer and incubating for 4 h (
NO
O24 h)
reverted the NO uptake rate back to the untreated RBC rate of NO uptake (n
4). (d) The increase in the NO uptake rate of NO-pretreated hypoxic RBCs
correlated with the formation of HbFe(II)NO (P 0.05, n 4 for each sample).
Fig. 2. The formation of HbFe(II)NO in hypoxic RBCs pretreated with NO was
measured by EPR. The signature three-peak hyperfine splitting demonstrated
that NO was primarily bound to the  heme subunit under hypoxia and was
primarily in the low-oxygen affinity T state (upper black line). On oxygenation,
NO remained bound to theheme subunit, whereas Hb converted to the high
oxygen affinity R state (lower gray line).
Table 1. HbFe(II)NO preferentially binds to the membrane
RBC fraction HbFe(II)NOtotal Hb 
 SD, %
Cytosol 0.49 
 0.08
Membrane 0.91 
 0.16*
*, P  0.01, n  5.
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control. Interestingly, when RBCs were pretreated with NO
under hypoxic conditions and introduced to the lumen (40%
Hct), 5-HT elicited a concentration-dependent vasoconstriction
response. Under this condition, the 5-HT-induced NO produc-
tion was negated by the increased NO consumption from the
pretreated RBCs, which allowed the 5-HT effect on smooth
muscle contraction to fully express. The resting myogenic tone
of the microvessels with buffer, RBCs pretreated with NO under
hypoxic conditions, or untreated RBCs did not differ (Fig. 3),
again indicating that NO was not exported from NO-pretreated
hypoxic RBCs. Lysis of pretreated or untreated RBCs resulted
in a significant increase in the resting tone, which was readily
discernable.
To detect the net export of NO or other vasoregulators that
may have occurred under these conditions, both NO-pretreated
hypoxic and untreated RBCs were tested in an isolated rat aortic
ring tissue preparation. Both types of RBCs elicited similar
contraction in phenylephrine precontracted aortic rings, sug-
gesting that no vasoregulatory bioactivity was exported by
hypoxic RBCs pretreated with NO under these conditions
(Table 2). This result is consistent with the constant resting tone
of the isolated microvessels containing NO-treated and un-
treated RBCs and is in contrast to NO export from NO-
pretreated RBCs under anaerobic (1% oxygen saturation) con-
ditions (17). Taken together, these data indicate that RBCs
pretreated with NO under hypoxic conditions consume NO
much more rapidly than untreated RBCs. Furthermore, these
pretreated RBCs exported neither vasodilatory nor vasocon-
strictive bioactivity under these experimental conditions.
Discussion
The above results demonstrated that NO consumption can be
regulated by the NO adduct with Hb in RBCs, and such
regulation is physiologically significant because it converts 5-HT
from a vasodilator to a vasoconstrictor. HbFe(II)NO was impli-
cated as the key in this regulation. This NO-heme adduct has
been detected at quantities as high as 10 M, in vivo (18), and
is increased from normal levels during NO inhalation therapy
(19). The formation of HbFe(II)NO proceeds by the direct
binding of NO to HbFe(II) during hypoxia, as occurs in the
pulmonary circulation where deoxygenated blood enters a vas-
cular bed in which NO is generated (20). Because HbFe(II)NO
has been detected in vivo under various conditions (21–29), the
increased NO entry into NO-pretreated hypoxic RBCs may have
significant implications in physiological, pathological, or clinical
situations where low oxygen tension and relatively high NO
concentrations coexist, such as in pulmonary circulation, NO
inhalation therapy, ischemia-related vasospasm, and sepsis.
A Potential Mechanism. The potential mechanism by which NO
uptake was increased may lie with the membrane skeleton,
because HbFe(II)NO was more abundant in the membrane than
in the cytosol (Table 1). In addition, the membrane skeleton has
been previously identified as a component in the reduced entry
of NO (4). Under conditions in which the NOheme ratio is low,
NO is bound primarily to the  heme moiety (-NO, Fig. 2). This
form of Hb has been characterized to exist in a ‘‘super T’’
allosteric state (13). Because the T state Hb binds to the
cytoplasmic domain (N terminus) of Band 3 tetramers in the
2,3-bisphosphoglycerate pocket (30), it is likely that -NO is
bound to Band 3 tetramers. Because the Band 3 tetramer is also
the site for ankyrin, which anchors the membrane skeleton to the
membrane (31), HbFe(II)NO may displace some ankyrin to
release the membrane skeleton from portions of the membrane.
This ‘‘loosening’’ effect may be the cause of the increased NO
uptake (Fig. 4a). Huang et al. (4) suggested a similar effect when
shifting the population of Band 3 to dimers. Band 3 dimers have
a lower affinity to ankyrin, thus reducing the association of the
membrane skeleton to the membrane (31). The formation of
small amounts of HbFe(II)NO in which NO is primarily bound
to the  heme has also been demonstrated to enhance oxygen
delivery to tissue without increasing blood flow (32). The
interaction between -NO and the membrane skeleton is likely
key to this regulation.
Implication to HPV. In the pulmonary circulation, HPV is a
response in which pulmonary arteries constrict on induction of
hypoxia, presumably to enhance blood oxygenation via shunting
of flow to the nonhypoxic sites (33). The mechanism of this
phenomenon has been extensively studied, yet a complete un-
derstanding is still lacking because of its complex and multifac-
torial nature (34). Previously, HPV has been demonstrated to be
greatly potentiated by RBCs (35, 36). Perfusion of isolated rat
lungs with RBC suspensions increased pulmonary arterial pres-
sure to a relatively stable plateau on induction of HPV (34, 37).
In contrast, perfusates void of RBCs elicited a much weaker
multiphasic response (34, 37). This observation may be ex-
plained, in part, by the increased NO uptake by RBCs, because
pulmonary arteries produce NO (20, 38), and the Hb oxygen
saturation is sufficiently low. The formation of HbFe(II)NO
would be possible in vessels where oxygen tension is locally low
due to the increased availability of free heme sites. Thus,
vasoconstriction may result in areas of lower oxygen tension.
Blood flow would be diverted to regions in the lungs that contain
more oxygen, thus enhancing blood oxygenation. Therefore,
increased uptake of NO by RBCs could be an important factor
contributing to HPV. In addition, Erzurum and coworkers (39)
have proposed that inducible NOS in the alveoli is an oxygen
sensor, which may have bearing on the phenomenon presented
here.
Fig. 3. The bioactivity of 5-HT was converted from vasodilation to vasocon-
striction by RBCs treated under hypoxia with NO. Addition of 5-HT to isolated
porcine arterioles containing buffer alone resulted in dose-dependent vaso-
dilation (n 9). The addition of untreated RBCs to the lumen of the arteriole
attenuated 5-HT-induced vasodilation, suggesting that some 5-HT-induced
NO is consumed by RBCs (n  5). Addition of 5-HT to arterioles containing
NO-pretreated RBCs resulted in vasoconstriction, suggesting that these RBCs
consumed NO more rapidly than untreated RBCs (n  5). The resting tone of
the arterioles did not differ with the addition of untreated or NO-pretreated
hypoxic RBCs to the vessel lumen, suggesting that lysis was minimal and no
export of vasodilatory or vasoconstrictive species occurred.
Table 2. Isolated rat aortic ring tissue preparations
Description Increase in vessel tone 
 SE, %
Untreated RBCs 41.5 
 9.1
NO-treated hypoxic RBCs 39.8 
 9.9
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Implication to NO Inhalation Therapy. During NO inhalation ther-
apy, the formation of HbFe(II)NO, along with other NO met-
abolic species, has been identified (19, 29, 40). NO inhalation is
typically used to provide relief for pulmonary hypertension (41).
On termination of NO inhalation therapy, a transient but
dramatic decrease in tissue oxygenation with an increase in
pulmonary arterial pressure beyond the baseline pressure has
been observed (42). The increased uptake of NO by RBCs
bearing HbFe(II)NOmay contribute to this ‘‘rebound’’ response
to NO inhalation therapy termination. Because HbFe(II)NO
formation is evident, it is likely that the entry of NO into the
RBC increases during NO inhalation therapy. On termination of
NO inhalation therapy, sufficient HbFe(II)NO exists in the RBC
to consume endogenously produced NO more rapidly, adding to
the rebound effect. Consistent with the instability of
HbFe(II)NO, the rebound effect is transient (42). Evidence that
NOS inhibition may also contribute to the increase in pulmonary
arterial pressure exists (43–45); however, whether inhibition
actually occurs is still a matter of debate (46, 47). RBCs, in
conjunction with other vasoconstrictors (48, 49), may mediate
the rebound effect seen on termination of NO inhalation
therapy.
Implication to Ischemic Vasospasm. It is well documented that
endothelial dysfunction is believed to play an important integral
part in the clinical presentation of coronary artery disease (50).
When the endothelium is damaged, the reduced NO and pros-
tacyclin production at the site leads to platelet aggregation with
the release of 5-HT and thromboxane A2, subsequently enhanc-
ing basal vascular tone and leading to a reduction of local blood
flow and ischemiahypoxia. Because NO production is increased
by inducible NOS induction in neutrophils, macrophages, and
cardiomyocytes in the inflammatory phase of myocardial isch-
emia and infarction (51–55), HbFe(II)NO is likely formed under
these conditions. In fact, HbFe(II)NO has been detected during
ischemia reperfusion (21, 24). NO consumption by RBCs bear-
ing HbFe(II)NO is expected to increase, which would further
potentiate vasoconstriction, as implicated in the present study. It
has been suggested that endothelial vasodilator dysfunction plays
a causative role for triggering myocardial ischemia in stable
angina pectoris (56). Increased NO consumption by RBCs would
aggravate the sequelae of acute ischemic syndrome and might be
the primary underlying mechanism in some patients with syn-
drome X (56).
Implication to Sepsis. Sepsis is a complicated disease state that
is the focus of much work (57). Sepsis occurs with the
infiltration of bacteria, which results in the activation of the
immune response. Sepsis is also known as the ‘‘systemic
inf lammatory response to infection,’’ or SIRS (58). Severe
sepsis leads to hypotension and organ dysfunction. Increased
production of NO, which is responsible for the hypotensive
state, has been documented to lead to the formation of
HbFe(II)NO (59, 60). To buffer the effects of high NO
concentrations, RBCs may have evolved a mechanism by which
excess NO is consumed more rapidly. The phenomenon pro-
posed here may be such a mechanism. By consuming excess
NO, HbFe(II)NO-bearing RBCs may stabilize the vasculature
in sepsis.
Conclusion
In summary, we have demonstrated that NO consumption by
RBCs can be regulated byHbFe(II)NO formation under hypoxic
conditions. As illustrated in Fig. 4b, on exposure to local hypoxia,
oxygen is released from HbFe(II)O2 to result in the formation
of HbFe(II). When hypoxic RBCs are exposed to NO,
HbFe(II)NO is formed, and the NO consumption rate increases.
This increase in NO consumption was shown to convert the
bioactivity of 5-HT to a vasoconstrictor in isolated coronary
arterioles. The increase in the NO uptake rate is reversible.
However, if hypoxic RBCs are first reoxygenated and then
exposed to NO, the RBC uptake rate does not change, and the
bioactivity of 5-HT remains vasodilatory. Interestingly, in con-
trast to a previous report (17), we did not find evidence of NO
export from NO-pretreated RBCs under aerobic or hypoxic
conditions. Finally, our results may represent a new paradigm of
physiological regulation of NO by alteration of its rate of
consumption and have significant implications in our under-
standing of the interactions of NO with RBCs in the vasculature.
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